Loading people...
Leighanne Oh is an Analyst at Sofinnova Investments based in Paris, Île-de-France, France, where she focuses on early-stage healthcare and deep tech investments. Joining the venture capital firm in September 2024, she recently participated in the close of Sofinnova's €150 million Health Tech Fund I in March 2025 and supports a broader portfolio of over 100 active companies. Prior to her current position, she served as an Analyst at Elaia Partners from 2022 to 2024, managing deal sourcing and due diligence across the broader European technology sector. She holds a Master's degree in Finance from HEC Paris and previously completed early-stage venture capital internships at Bpifrance and Serena Capital. Oh's current focus centers on identifying emerging opportunities in biotechnology and climate tech, recently speaking at the Slush 2025 conference regarding artificial intelligence in drug discovery.
Leighanne Oh is a key member of the investment team at Sofinnova Investments, where she holds the title of Analyst. In this capacity, Leighanne is deeply involved in the intricate process of sourcing, evaluating, and conducting due diligence on potential investment opportunities. Her work is instrumental in supporting Sofinnova's mission to back groundbreaking companies that are poised to revolutionize the life sciences and healthcare landscape.
Sofinnova Investments is renowned for its focus on early-stage biotechnology, pharmaceutical, and medical device companies. Leighanne's investment focus areas align with the firm's broader strategy, encompassing novel therapeutics, innovative diagnostics, and disruptive healthcare technologies. She is particularly interested in scientific advancements that address significant unmet medical needs and have the potential for transformative patient impact. Her analytical skills are vital in assessing the scientific merit, market potential, and competitive landscape of prospective portfolio companies.
Leighanne's career background likely reflects a strong foundation in science and a growing expertise in the business of biotechnology. While specific details of her pre-Sofinnova career are not publicly detailed, individuals in her role typically possess advanced degrees in life sciences, such as biology, biochemistry, or genetics, often coupled with experience in research, consulting, or early-stage company development. This robust background equips her with the critical understanding necessary to dissect complex scientific data and evaluate the commercial viability of cutting-edge innovations.
As an Analyst, Leighanne contributes significantly to the firm's overall portfolio success rather than leading individual investments. Her efforts support the partners and principals in making informed decisions that shape Sofinnova's diverse portfolio. While specific 'notable investments' attributed solely to an Analyst are uncommon, her analytical contributions are integral to every deal the firm pursues, helping to identify the next generation of life science leaders. Her dedication ensures that Sofinnova Investments continues to identify and nurture companies that promise to deliver significant advancements in human health.
Leighanne Oh is an Analyst at Sofinnova Investments, a leading venture capital firm focused on the life sciences sector. She is involved in identifying and evaluating early-stage biotech and healthcare investment opportunities.
As an Analyst at Sofinnova Investments, Leighanne Oh contributes to investments in early-stage biotechnology, pharmaceuticals, and medical devices. Her focus areas align with the firm's strategy of backing novel therapeutics, diagnostics, and disruptive healthcare technologies.
Leighanne Oh works at Sofinnova Investments, a prominent venture capital firm dedicated to investing in innovative companies within the life sciences and healthcare industries.
